CN106255501A - 用于治疗阿尔茨海默氏病的6‑取代的雌二醇衍生物 - Google Patents

用于治疗阿尔茨海默氏病的6‑取代的雌二醇衍生物 Download PDF

Info

Publication number
CN106255501A
CN106255501A CN201580014623.7A CN201580014623A CN106255501A CN 106255501 A CN106255501 A CN 106255501A CN 201580014623 A CN201580014623 A CN 201580014623A CN 106255501 A CN106255501 A CN 106255501A
Authority
CN
China
Prior art keywords
methyl
cyclopenta
phenanthrene
glycol
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580014623.7A
Other languages
English (en)
Chinese (zh)
Inventor
J·G·亚格尔
S·H·奈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endece LLC
Original Assignee
Endece LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endece LLC filed Critical Endece LLC
Publication of CN106255501A publication Critical patent/CN106255501A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201580014623.7A 2014-03-19 2015-03-19 用于治疗阿尔茨海默氏病的6‑取代的雌二醇衍生物 Pending CN106255501A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461955578P 2014-03-19 2014-03-19
US61/955,578 2014-03-19
PCT/US2015/021538 WO2015143201A2 (en) 2014-03-19 2015-03-19 6-substituted estradiol derivatives for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
CN106255501A true CN106255501A (zh) 2016-12-21

Family

ID=54141046

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580014623.7A Pending CN106255501A (zh) 2014-03-19 2015-03-19 用于治疗阿尔茨海默氏病的6‑取代的雌二醇衍生物

Country Status (11)

Country Link
US (1) US20150265630A1 (https=)
EP (1) EP3119402A4 (https=)
JP (1) JP2017512769A (https=)
KR (1) KR20160136363A (https=)
CN (1) CN106255501A (https=)
AU (2) AU2015231172A1 (https=)
BR (1) BR112016021408A2 (https=)
CA (1) CA2940536A1 (https=)
MX (1) MX2016012045A (https=)
SG (1) SG11201607693WA (https=)
WO (1) WO2015143201A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020247407A1 (en) * 2019-06-03 2020-12-10 Aihol Corporation Hyaluronan conjugates and uses thereof
US20210024568A1 (en) * 2019-07-23 2021-01-28 Endece Llc Methods for modulation of lipoprotein lipase and apolipoprotein c2 expression and/or activity in the treatment of peripheral and central nervous system tissue disease states

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103501790A (zh) * 2011-03-21 2014-01-08 安德斯有限责任公司 用于神经轴突的髓鞘再生的6-取代的雌二醇衍生物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10174070B2 (en) * 2005-09-30 2019-01-08 Endece Llc 6-substituted estradiol derivatives and methods of use
US20080200441A1 (en) * 2007-02-14 2008-08-21 University Of Southern California Estrogen receptor modulators associated pharmaceutical compositions and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103501790A (zh) * 2011-03-21 2014-01-08 安德斯有限责任公司 用于神经轴突的髓鞘再生的6-取代的雌二醇衍生物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DONALD POIRIER, ET AL.: "Inhibitors of type II 17β-hydroxysteroid dehydrogenase", 《MOLECULAR AND CELLULAR ENDOCRINOLOGY》 *
符晓苏 等: "阿尔茨海默病与性激素水平的关系研究", 《实用老年医学》 *

Also Published As

Publication number Publication date
JP2017512769A (ja) 2017-05-25
EP3119402A2 (en) 2017-01-25
SG11201607693WA (en) 2016-10-28
BR112016021408A2 (pt) 2017-12-19
KR20160136363A (ko) 2016-11-29
EP3119402A4 (en) 2017-11-01
AU2015231172A1 (en) 2016-09-08
CA2940536A1 (en) 2015-09-24
MX2016012045A (es) 2017-01-19
WO2015143201A2 (en) 2015-09-24
AU2018201003A1 (en) 2018-03-01
US20150265630A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
EP3872077B1 (en) Heterocyclic amide for inhibiting rip1 kinase and uses thereof
JP6732906B2 (ja) ピリミジン誘導体及びその使用
CN116554168A (zh) Cxcr4抑制剂及其用途
RU2711382C2 (ru) 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2
TWI342309B (en) Novel fused pyrrolocarbazoles
CN116171153A (zh) 用于调节剪接的组合物
Park et al. Involvement of AMPA receptor and its flip and flop isoforms in retinal ganglion cell death following oxygen/glucose deprivation
JP2004523486A (ja) ヒトｅｒｇ２カリウムチャンネル
CN103857400B (zh) 玫瑰红景天提取物和分离的化合物及其在治疗神经变性疾病中的应用
CN112189009A (zh) 作为tcr-nck相互作用的抑制剂的色烯衍生物
WO2024181437A1 (ja) Ｍｙｔ１阻害活性を有する含窒素複素環化合物
CN106255501A (zh) 用于治疗阿尔茨海默氏病的6‑取代的雌二醇衍生物
KR20250151389A (ko) 치환 피라졸로피리미딘 화합물 및 그의 의약 용도
CN103501790B (zh) 用于神经轴突的髓鞘再生的6-取代的雌二醇衍生物
AU2023314261A1 (en) Therapeutic uses of urolithin derivatives
US9399644B2 (en) [1,3] dioxolo [4,5-G] quinoline-6(5H)thione derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer
SA109300406B1 (ar) ثينيل- وفيرانيل أيزوكوينولينونات وطرق لاستخدامها
WO2024222379A1 (zh) 哒嗪酮类trpc4/5抑制剂及其用途
WO2025255245A1 (en) Compounds and their use in treating medical conditions
WO2025045248A1 (zh) 联芳环类化合物、其中间体、制备方法和应用
WO2019046534A1 (en) INDOLOQUINOLINE COMPOUNDS DEUTTERED

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20161221